Navigation Links
Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
Date:5/3/2013

SAN DIEGO, May 3, 2013 /PRNewswire/ -- Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

Under terms of the agreement, Ambrx will receive an upfront payment of $15 million, funding for discovery and research activities, and potential development, regulatory and sales based milestone payments of up to $97 million per product resulting from the collaboration. Bristol- Myers Squibb will receive worldwide rights to develop and commercialize products resulting from the collaboration, and Ambrx is eligible to receive royalties on net sales. Additional terms were not disclosed.

"Bristol-Myers Squibb is a global biopharmaceutical leader with expertise developing and commercializing novel medicines for the treatment of cancer and other diseases, and we are pleased to enter into a third collaboration with the company to include another aspect of our technology platform," said Lawson Macartney , Ph.D., chief executive officer of Ambrx. "We look forward to working together to further utilize Ambrx's technology to discover and advance these antibody drug conjugates for oncology indications."

Ambrx and Bristol-Myers Squibb entered into two separate agreements in September 2011 to research, develop and commercialize biologics created with Ambrx's protein medicinal chemistry technology. These therapeutic candidates, which target the Fibroblast Growth Factor 21 (FGF-21) protein for the potential treatment of type 2 diabetes, and the Relaxin hormone for the potential treatment of heart failure, are being developed by Bristol-Myers Squibb.

About Ambrx
Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including antibody drug conjugates, bispecific antibodies and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. In addition to its three collaborations with Bristol-Myers Squibb, Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Astellas, Merck, Eli Lilly and Company and several undisclosed companies.  Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit www.ambrx.com.

Media Contacts:
Ian Stone
(619) 308-6541

David Schull
(212) 845-4271


'/>"/>
SOURCE Ambrx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
6. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
7. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
10. Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)
11. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2019)... ... 15, 2019 , ... Mold doesn’t need things to be wet in order ... detectable to the eye or by touch. ServPro in Cayucos , the mold ... explaining the conditions that mold needs to grow and how to prevent those conditions. ...
(Date:11/14/2019)... ... 2019 , ... Researchers at Worcester Polytechnic Institute (WPI) are ... blood oxygen levels, a vital indication of the lungs’ effectiveness and whether the ... this miniaturized wearable device will be flexible and stretchable, wireless, inexpensive, and mobile—possibly ...
(Date:11/14/2019)... (PRWEB) , ... November 14, 2019 , ... ... K-FISH, aimed to promote the quality of Korean seafood and enhance its global ... entitled, "K-Seafood Global Weeks" in many countries. These special events are currently ...
Breaking Medicine Technology:
(Date:11/11/2019)... ... November 11, 2019 , ... Early praise for A ... down the complexities of scholarly writing and provides key insight and vital guidance for ... DNP Project will have a permanent place on my bookshelf and will be shared ...
(Date:11/11/2019)... Calif. (PRWEB) , ... November 11, 2019 , ... ... of business support services to dental groups in the United States, today announced ... the community of Lodi, CA. , Patients will enjoy convenient hours, comfortable offices ...
(Date:11/11/2019)... LAS VEGAS (PRWEB) , ... November 11, 2019 , ... ... buyers from 46 different countries including big box buyers like Costco, Walmart, and GNC. ... CBDfx, and GRN to name a few. , This year, CBD.io ...
(Date:11/11/2019)... ... November 11, 2019 , ... Artemis, ... prevention and urges increased adoption of compliance technology in the wake of the ... sold to select retailers in the United States and Canada due to potential ...
(Date:11/11/2019)... ... 11, 2019 , ... PracticeLink Live! Atlanta Physician Career Fair will take place ... 5:00 p.m. and continue until 8:00 p.m. A free, optional seminar for job-seeking physicians, ... 6:30 p.m. , Both the career fair and seminar are open to residents and ...
Breaking Medicine News(10 mins):